EUROASPIRE.
A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.Eur Heart J1997;
18: 1569–1582.
2.
GroupEIS.Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J2001;
22: 554–572.
3.
KotsevaKWoodDDe BackerG, et al.
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil2009;
16: 121–137.
4.
KotsevaKWoodDDe BacquerD, et al.
EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol2016;
23: 636–648.
5.
KotsevaKDe BackerGDe BacquerD, et al.
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol2019;
26: 824–835.
6.
SantosRD.Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself. Eur J Prev Cardiol2019;
26: 820–823.
7.
BlomDJSantosRDDaclinV, et al.
The challenge of multiple cardiovascular risk factor control outside Western Europe: findings from the International ChoLesterol management Practice Study. Eur J Prev Cardiol, Epub ahead of print 19 September 2019. DOI: 10.1177/2047487319871735.
8.
GrundySMStoneNJBaileyAL, et al.
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol2019;
73: e285–e350.
9.
MachFBaigentCCatapanoAL, et al.
2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J2020;
41: 111–188.
10.
FruchartJCDavignonJHermansMP, et al.
Residual macrovascular risk in 2013: what have we learned?Cardiovasc Diabetol2014;
13: 26.
11.
RochaVZSantosRD.Cholesterol and inflammation: the lesser the better in atherothrombosis. Eur J Prev Cardiol2018;
25: 944–947.
12.
ConnollySJEikelboomJWBoschJ, et al.
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet2018;
391: 205–218.
13.
TsimikasSFazioSFerdinandKC, et al.
NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol2018;
71: 177–192.
14.
FruchartJCSantosRDAguilar-SalinasC, et al.
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol2019;
18: 71.
15.
RobinsonJGWilliamsKJGiddingS, et al.
Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life. J Am Heart Assoc2018;
7: e009778.
16.
FerenceBABhattDLCatapanoAL, et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA 2019; 322: 1381–1391.
17.
TaylorFHuffmanMDMacedoAF, et al.
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev2013;
1: CD004816.
18.
EttehadDEmdinCAKiranA, et al.
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet2016;
387: 957–967.
19.
WangNFulcherJAbeysuriyaN, et al.
Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol2020;
8: 36–49.
20.
Cholesterol Treatment Trialists’ Collaborators, MihaylovaBEmbersonJ, et al.
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet2012;
380: 581–590.
21.
De BackerG.Epidemiology and prevention of cardiovascular disease: Quo vadis?Eur J Prev Cardiol2017;
24: 768–772.
22.
KotsevaKDBGDe BacquerDRydenL, et al.; EUROASPIRE V Investigators. Primary prevention efforts are poorly developed in people at high cardiovascular risk. A report from the ESC-EORP EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol, Epub ahead of print 20 March 2020. DOI: 10.1177/2047487320908698.
23.
KalraRParchaVPatelN, et al.
Increased awareness, inadequate treatment, and poor control of cardiovascular risk factors in American young adults: 2005-2016. Eur J Prev Cardiol, Epub ahead of print 2 March 2020. DOI: 10.1177/2047487320905190.
24.
KatzMLaurinaviciusAGFrancoFG, et al.
Calculated and perceived cardiovascular risk in asymptomatic subjects submitted to a routine medical evaluation: the perception gap. Eur J Prev Cardiol2015;
22: 1076–1082.
25.
LindahlBNorbergMJohanssonH, et al.
Health literacy is independently and inversely associated with carotid artery plaques and cardiovascular risk. Eur J Prev Cardiol2020;
27: 209–215.
26.
AlcalaHEAlbertSLRobyDH, et al.
Access to care and cardiovascular disease prevention: a cross-sectional study in 2 Latino communities. Medicine (Baltimore)2015;
94: e1441.
